E Bartholomé

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Stroke Presentation and Outcome in Developing Countries

Johanne Garbusinski, Marianne A. B. van der Sande, E Bartholomé et al. · Stroke · 2005 · 125 citations · Full text

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 103 citations

Relapsing-remitting Multiple Sclerosis, Clinical Neurology, Clinical Trials +8

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing‐remitting multiple sclerosis

Shibeshih Belachew, Rémy Phan-Ba, E Bartholomé et al. · European Journal of Neurology · 2010 · 82 citations · Full text

Interleukin-3 and interferon β cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties

Christel Buelens, E Bartholomé, Zoulikha Amraoui et al. · Blood · 2002 · 81 citations · Full text